Search

17 Jul 2024: the animal antibody with human equivalents – for the drug to be successful in humans. ... in the marketplace./p pTechnology licensing, the core of Cambridge Enterprise’s business, had another successful year with 109 licences completed.

17 Jul 2024: rel="noopener noreferrer"Cambridge Epigenetix/a,a pioneer in the development of epigenetic sequencing. ... It dates back almost 10 years before the anniversary that Cambridge Enterprise is now celebrating.

17 Jul 2024: Schmitt, Technology Manager at Cambridge Enterprise, the University’s commercialisation group, said “Studying the functions of genes in mammals is enormously difficult. ... cells with single chromosome set/a appeared first on a

17 Jul 2024: cam.ac.uk/news/wound-care-company-nobacz-healthcare-ltd-closes-2-7m-seed-round/ Jo Tramontin Fri, 31 Mar 2023 12:47:26 0000 Life Sciences Spin-outs Ventures animals ... round/a appeared first on a href="https://www.enterprise.cam.ac.uk"Cambridge

17 Jul 2024: the animal antibody with human equivalents – for the drug to be successful in humans. ... Cambridge researchers/a appeared first on a href="https://www.enterprise.cam.ac.uk"Cambridge Enterprise/a./p.

17 Jul 2024: said: “We are delighted to have closed the funding round with Cambridge Enterprise and the University of Cambridge Enterprise Fund. ... We are delighted to close this investment on behalf of the University of Cambridge Enterprise Fund.

17 Jul 2024: Eventually, however, performance degrades and the batteries must be recycled, as lead is highly toxic to plants and animals./p div class="stat alignright"The Cambridge process uses about 8% of ... a appeared first on a

17 Jul 2024: the animal antibody with human equivalents – for the drug to be successful in humans. ... first on a href="https://www.enterprise.cam.ac.uk"Cambridge Enterprise/a./p.

17 Jul 2024: across the research of Professor Martin of the Clinical Neurosciences Group at the University of Cambridge and sought collaboration. ... a appeared first on a href="https://www.enterprise.cam.ac.uk"Cambridge Enterprise/a./p.

17 Jul 2024: of Cambridge gene therapy spin-out is developing a treatment that could prevent the deleterious effects of glaucoma, the leading cause of irreversible blindness worldwide. ... across the research of Professor Martin of the Clinical Neurosciences Group at